WO2004012753A1 - Composition pharmaceutique contenant de l'huile de nigelle, de lin et de bourrache - Google Patents
Composition pharmaceutique contenant de l'huile de nigelle, de lin et de bourrache Download PDFInfo
- Publication number
- WO2004012753A1 WO2004012753A1 PCT/IB2003/003054 IB0303054W WO2004012753A1 WO 2004012753 A1 WO2004012753 A1 WO 2004012753A1 IB 0303054 W IB0303054 W IB 0303054W WO 2004012753 A1 WO2004012753 A1 WO 2004012753A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oil
- mass
- composition
- acid
- black cumin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/55—Linaceae (Flax family), e.g. Linum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Definitions
- This invention relates to an enteral pharmaceutical composition for the treatment of multiple sclerosis.
- Multiple sclerosis is caused by damage to the myelin sheath which covers the axons of neurons. Nerve signals travel from neuron to neuron via axons.
- the myelin sheath serves as an insulation against signal loss to neighbouring tissue. A damaged myelin sheath leads to a distortion or complete disappearance of signals.
- the myelin sheath is sub-divided into distinct sections which are separated from each other by nodes, which are called "Nodes of Ranvier".
- Nodes of Ranvier The latter's function is to speed up the transmission of nerve signals.
- Damage to the myelin sheath therefore not only distorts or leads to the complete loss of nerve signals, but also slows down their transmission from neuron to neuron. This, in essence, is the nature of the phenomenon known as multiple sclerosis. As the damage to the myelin sheaths progresses, the patient affected by the disease loses control of essential body functions: loss of balance, slow and shaky walking patterns, speech impediment, even loss of bladder control and other symptoms.
- Myelin is a very complex substance, consisting of various fats, fatty acids, phospho-lipids, proteins and even cholesterol.
- an enteral pharmaceutical composition containing black cumin oil (nigella saliva), flax oil (olelum lini) and borage oil (borago officinalis) for the treatment of multiple sclerosis.
- the invention also relates to a method of treating multiple sclerosis using the aforementioned pharmaceutical composition, and to the use of black cumin oil, flax oil and borage oil in a method of making a medicament for use in a method of treating multiple sclerosis.
- the composition typically contains 70 to 80% by mass, preferably 75% by mass flax oil; 10% to 20% by mass, preferably 15% by mass black cumin oil; and 5% to 15% by mass, preferably 10% by mass borage oil.
- an enteral pharmaceutical composition for treating multiple sclerosis the composition containing 65% to 75% by mass polyunsaturated fatty acids wherein one of the polyunsaturated fatty acids is gamma-linolenic acid.
- the other polyunsaturated fatty acids may be selected from alpha-linolenic acid and linoleic acid.
- the composition contains 1% to 10 % by mass gamma- linolenic acid.
- the pharmaceutical composition contains, by mass of the composition:
- Alpha-Linolenic Acid 40% to 50%, preferably 45%
- Gamma-Linolenic Acid 1 % to 5%, preferably 2%
- the composition also contains enzymes, preferably desaturase enzymes such as delta-6-desaturase.
- the composition also contains vitamins, preferably vitamins B3, B6 and C, and minerals, preferably zinc and magnesium.
- This invention relates to an enteral pharmaceutical composition for the treatment of multiple sclerosis.
- the pharmaceutical composition includes black cumin oil (nigella sativa), flax oil (oleium lini), borage oil (borago officinalis) and vitamins and minerals.
- Black cumin oil is composed of the following fatty acids by mass:
- Flax oil is composed of the following fatty acids by mass: Omega 3 (Linolenic) 60.1 %
- Borage oil is composed of the following fatty acids by mass: Gamma-Linolenic acid 22%
- the flax oil, borage oil and black cumin oil are mixed at a percentage 75%, 10% and 15% by mass respectively to provide a medicinal composition according to the invention. These percentages may vary, depending on the individual's requirements.
- the composition When taken enterally the composition has been shown to treat multiple sclerosis successfully.
- the dosage of the composition depends on the severity of the multiple sclerosis and the patient, but a usual dosage is 20ml to 40ml per day, typically 20ml per day.
- composition of the invention provides an abundance of polyunsaturated fatty acids which are believed to be the building materials for the formation of myelin, the breakdown of which is believed to be the root cause of multiple sclerosis.
- This abundance of fatty acids is provided by the flax oil, the black cumin oil and the borage oil.
- the enzymes required for essential fatty acids metabolism are delta-6, delta-5 and delta-4-desaturase, of which delta-6-desaturase is the most important because if its function is impaired for whatever reasons, the other two enzymes have nothing to work with. It may also be that delta-6-desaturase is not produced by the body in sufficient quantities, which leads to the same malfunction.
- the borage oil contains gamma-linolenic acids, a substance normally produced in the human body by the enzyme delta-6-desaturase acting on dietary linoleic acid through a process known as desaturation and elongation.
- gamma-linolenic acid is therefore available for subsequent metabolic conversions even if no or to little delta-6-desaturase is present.
- Borage seeds are also a source of delta-6- desaturase, thus making a basic supply of delta-6-desaturase available for the relevant conversions of fatty acids, not only into gamma-linolenic acid but also dihomo-gamma-linolenic acid, from which arachidonic acid and other essential fatty acid derivatives are formed.
- Enzymes require so-called co-factors in order to properly perform their functions.
- the co- factors are the vitamins B3, B6, and C and the minerals zinc and magnesium. Even an abundance of enzymes will not be able to effect the proper essential- fatty-acid metabolisms even if only one of the co-factors is not available in sufficient quantities. As a consequence, the complex end products of said metabolism, arachidonic acid with 4 double bonds, and docosahexaenoic acid, with 6 double bonds, will not be available in sufficient quantities.
- fatty acids are "brain fatty acids", meaning that they are incorporated into various brain structures, playing a vital role in the formation of myelin, and the transmission of nerve signals.
- Multiple sclerosis sufferers are therefore not only affected by a lack of available essential fatty acids, but also by a lack of available enzymes and/or a lack of available co-factors.
- Borage seeds contain the enzyme delta-6-desaturase, which is therefore made available through the oil, as an oil-soluble substance and/or through seed particles which are purposely left in the oil after cold-pressing. Therefore, even if a patient is lacking the enzyme delta-6-desaturase, it is made available through the borage oil and seed component of the present invention.
- 750ml flax oil is mixed with 100ml of borage oil and 150ml of black cumin oil to provide a preparation which is made up by the following by mass of the composition:
- composition also comprised 0,1g vitamin B6, 0,1g vitamin B3, 5g vitamin C, 14g magnesium and 0,6g zinc.
- Example 2
- Example 1 She began using the composition described in Example 1 at a dosage of 20ml per day. Her condition improved after 4 to 6 weeks. Approximately 3 months after beginning to use the composition of the invention she was practically symptom free and after 15 months she was still practically symptom free.
- Example 1 In May 2002, the patient started using the composition of Example 1 at a dosage of 20ml per day. Within 4 months, his condition had improved to such an extent that he was practically symptom-free.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003255863A AU2003255863A1 (en) | 2002-07-31 | 2003-07-31 | Pharmaceutical composition containing black cumin oil, flax oil and borago oil |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA200206088 | 2002-07-31 | ||
ZA2002/6088 | 2002-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004012753A1 true WO2004012753A1 (fr) | 2004-02-12 |
Family
ID=31496348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2003/003054 WO2004012753A1 (fr) | 2002-07-31 | 2003-07-31 | Composition pharmaceutique contenant de l'huile de nigelle, de lin et de bourrache |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003255863A1 (fr) |
WO (1) | WO2004012753A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1713463A2 (fr) * | 2004-01-19 | 2006-10-25 | Martek Biosciences Corporation | Dysfonctionnement ou d ficit de reelin et techniques associ es |
US20100087533A1 (en) * | 2007-02-16 | 2010-04-08 | John Allan Howie | Composition |
WO2022015209A1 (fr) * | 2020-07-15 | 2022-01-20 | مهرة المطيري | Formulation à base de composants naturels pour traiter la sclérose en plaques |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4058594A (en) * | 1974-04-25 | 1977-11-15 | John Williams | Immuno-suppressive agents |
EP0347056A1 (fr) * | 1988-06-10 | 1989-12-20 | Scotia Holdings Plc | Compositions d'acides gras essentiels |
EP0520624A1 (fr) * | 1991-06-03 | 1992-12-30 | Scotia Holdings Plc | Composition alimentaire, pharmaceutique et cosmétique contenant di-linoléoyle-mono-gamma linolényle-glycérole |
WO2000032211A1 (fr) * | 1998-12-03 | 2000-06-08 | Crede, Thomas | Preparation pharmaceutique enterale |
-
2003
- 2003-07-31 AU AU2003255863A patent/AU2003255863A1/en not_active Abandoned
- 2003-07-31 WO PCT/IB2003/003054 patent/WO2004012753A1/fr not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4058594A (en) * | 1974-04-25 | 1977-11-15 | John Williams | Immuno-suppressive agents |
EP0347056A1 (fr) * | 1988-06-10 | 1989-12-20 | Scotia Holdings Plc | Compositions d'acides gras essentiels |
EP0520624A1 (fr) * | 1991-06-03 | 1992-12-30 | Scotia Holdings Plc | Composition alimentaire, pharmaceutique et cosmétique contenant di-linoléoyle-mono-gamma linolényle-glycérole |
WO2000032211A1 (fr) * | 1998-12-03 | 2000-06-08 | Crede, Thomas | Preparation pharmaceutique enterale |
Non-Patent Citations (2)
Title |
---|
HARBIGE L S ET AL: "The protective effects of omega-6 fatty acids in experimental autoimmune encephalomyelitis (EAE) in relation to transforming growth factor-beta 1 (TGF-beta1) up-regulation and increased prostaglandin E2 (PGE2) production", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 122, no. 3, December 2000 (2000-12-01), &, pages 445 - 452, XP002263545, ISSN: 0009-9104 * |
TREMLETT H L ET AL: "Nonprescription medicine use in a multiple sclerosis clinic population", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, vol. 50, no. 1, July 2000 (2000-07-01), &, pages 55 - 60, XP002263546, ISSN: 0306-5251 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1713463A2 (fr) * | 2004-01-19 | 2006-10-25 | Martek Biosciences Corporation | Dysfonctionnement ou d ficit de reelin et techniques associ es |
EP1713463A4 (fr) * | 2004-01-19 | 2009-03-18 | Martek Biosciences Corp | Dysfonctionnement ou d ficit de reelin et techniques associ es |
US20100087533A1 (en) * | 2007-02-16 | 2010-04-08 | John Allan Howie | Composition |
WO2022015209A1 (fr) * | 2020-07-15 | 2022-01-20 | مهرة المطيري | Formulation à base de composants naturels pour traiter la sclérose en plaques |
Also Published As
Publication number | Publication date |
---|---|
AU2003255863A1 (en) | 2004-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102390608B1 (ko) | 편두통 증상을 관리하기 위한 글리세릴 3-하이드록시부티레이트 | |
Horrobin | Fatty acid metabolism in health and disease: the role of Δ-6-desaturase | |
Chen et al. | Chewing maintains hippocampus-dependent cognitive function | |
Greenwood et al. | Glucose treatment reduces memory deficits in young adult rats fed high-fat diets | |
CA2853971C (fr) | Composition servant a ameliorer la reconnaissance | |
US5668174A (en) | Method of treating hyperparathyroidism | |
DE60207877T2 (de) | Zusammensetzung enthaltend Procyanidine zur Verminderung des Appetits bei Säugetieren | |
EP0347056A1 (fr) | Compositions d'acides gras essentiels | |
AU2012235869B2 (en) | Compositions for the treatment of neurologic disorders | |
NO20063328L (no) | Anvendelse av en fettsyresammensetning som innbefatter minst en av EPA og DHA eller kombinasjoner derav | |
WO2006040324A1 (fr) | Compositions contenant des acides gras omega-3 et omega-6 | |
Zafar et al. | Calotropis procera (root) escalates functions rehabilitation and attenuates oxidative stress in a mouse model of peripheral nerve injury. | |
WO2004012753A1 (fr) | Composition pharmaceutique contenant de l'huile de nigelle, de lin et de bourrache | |
EP1526850B1 (fr) | Utilisation de la vitamine C pour le traitement de la maladie de Charcot-Marie-Tooth | |
US20110218151A1 (en) | Substances for promoting healthy joint function comprising omega-3 polyunsaturated fatty acids or drivatives thereof, undenatured type ii collagen and, optionally, glucosamine sulfate | |
DE69934325T2 (de) | Zusammenstellungen zur erhöhung der darmabsoption von fetten | |
Semen et al. | Towards improved pharmacotherapy in pulmonary arterial hypertension. Can diet play a role? | |
US20140256813A1 (en) | Methods for the treatment of brain injury using omega-3 fatty acids | |
DE102006011922A1 (de) | Mittel zur Behandlung von Tinnitus | |
US20110217370A1 (en) | Substances for promoting healthy joint function comprising glucosamine sulfate, omega-3 polyunsaturated fatty acids or derivatives thereof, and undenatured type ii collagen | |
Šunderić et al. | Is there something fishy about fish oil? | |
DE10056351A1 (de) | Pharmazeutisches Präparat | |
Marietta et al. | The supplementation effect of Red Dragon fruit's skin extract on the fasting blood glucose and lipid profiles in male Wistar rats with diabetes mellitus and dyslipidemia | |
WO2024067576A1 (fr) | Utilisation de bilobalide dans la préparation d'un médicament pour prévenir ou traiter le diabète et les complications diabétiques | |
Iwayama | Masticatory Deficiency and Deficit of Cognitive Function, Attention, Learning and Memory |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |